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Amal M. Alenad1, Majed s. Alokail1 & Mario Clerici1,3,4
Spexin (SPX) is a novel peptide thought to have a role in various metabolic regulations. Given its 
presumed body-weight regulatory functions, we aimed to determine whether lifestyle intervention 
programs on weight loss and fasting glucose (FG) improvement among people with impaired glucose 
regulation also alter levels of circulating SPX. A total of 160 Saudi adult males and females with 
prediabetes were randomly selected from a larger cohort (N = 294) who underwent a 6-month lifestyle 
modification program to improve their glycemic status. Participants were split into two groups based 
on differences in glucose levels post-intervention, with the first 50% (improved group) having the most 
significant reduction in FG. SPX was measured at baseline and after 6 months. Changes in SPX was 
significant only in the improved group [baseline: median (Q1–Q3) of 164 pg/ml (136–227) vs follow-up: 
176 pg/ml (146–285); p < 0.01]. When stratified by sex, the significant increase was observed only 
in females [159 pg/ml (127–252) vs 182.5 (152,369.1); p < 0.01]. Furthermore, SPX levels showed a 
significant inverse association with FG (β = −0.22, p = 0.003) even after adjustment with age and BMI, 
again only in females. Circulating SPX levels increase over time in people with prediabetes, particularly 
women who responded favorably in a 6-month lifestyle intervention program. Whether an unknown 
mechanism regulating the sexual disparity seen in SPX levels post-intervention exists should be further 
investigated using a larger sample size.
Spexin (SPX) is a newly identified neuropeptide with emerging roles in many metabolic processes such as sati-
ety, pubertal growth and reproduction1,2. Discovered through bioinformatics approach using Markov model 
screening3, SPX consists of 14 amino acids and belongs to spexin/galanin/kisspeptin gene family4. SPX is widely 
expressed in a number of rat tissues such as liver, testis, ovary, adrenal gland, etc., making it a promising bio-
marker in pathological disorders such as the metabolic syndrome, diabetes and others5.
SPX studies in animal models like fish and rodents revealed its role in various metabolic regulations. In 2014, 
Walewski et. al. showed that SPX regulates satiety in mice, possibly by inhibiting the uptake of long chain fatty 
acids into hepatocytes and adipocytes, resulting in weight loss6. Similar results confirmed the role of SPX as a 
regulator of fatty acid uptake in adipocytes and hepatocytes in fish7 and mice models8, respectively. Their results 
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suggest that this neuropeptide hormone is an adipocyte-secreted body-weight control factor. In humans, recent 
studies revealed that the levels of circulating SPX are significantly lower in obese women and children than the 
lean ones, suggesting a link between SPX and body weight regulation9,10. Despite the emerging evidence on the 
role of SPX in many physiological processes, knowledge on the functions of SPX, its expression, secretion, and 
influence on tissues, at least in humans, are still in its preliminary stages. However, taking into account SPX’s 
metabolic role, it is interesting to investigate its functions in insulin resistance (IR) and glucose homeostasis in 
type 2 diabetes mellitus (T2DM).
T2DM is associated with disturbances in glucose homeostasis and has a huge impact on the overall health care 
cost of the country. Landmark lifestyle intervention studies focusing on people with impaired glucose regulation 
(prediabetes) such as the Diabetes Prevention Program (DPP)11 and others12,13, revealed that progression into 
T2DM can be delayed. Such lifestyle intervention programs in high risk populations, done in the last two decades 
all over the world, focus mainly on weight loss, increased physical activity and reduction of fasting glucose. Since 
SPX has a possible relation with glucose homeostasis, it is interesting to study whether these lifestyle intervention 
programs, focusing on weight loss; increased physical activity and reduction of fasting glucose also modify levels 
of SPX. The present study aimed to observe changes in SPX levels over time after 6 months of lifestyle modifica-
tion program given to adult men and women with pre-diabetes. Additionally, we investigated the relationship of 
SPX with fasting glucose and other glycemic indices in these participants.
Results
Characteristics of Groups across Time Points. Table 1 shows the anthropometrics and biochemical 
characteristics of the study participants at baseline and end of the study. 160 subjects were divided into two 
groups: non-improved group (N = 80%, change in FG = median (IQR) = 1.57 (3.4); mean age = 43.37 ± 8.8 years) 
and improved group (N = 80%, change in FG = −22 (10.6); mean age = 43.32 ± 9.4 years). The table also shows 
the differences between the two groups at baseline. Baseline anthropometric and other measured biochemical 
characteristics were not statistically significant in both groups (depicted by PA in Table 1) except in fasting glucose 
(6.31 ± 0.5 mmol/l in non-improved group vs 6.14 ± 0.4 mmol/l in the improved group, p = 0.02).
As expected, mean fasting glucose (mmol/l) in the non-improved group did not change significantly from 
baseline to end of study (p = 0.62). The mean fasting glucose significantly in the improved group over time (mean 
change of −1.19 mmol/l, p < 0.01). Correspondingly, there was a significant decrease in weight (mean change 
of −1.44 kgs, p < 0.01), BMI (mean change of −0.55 kg/m2, p = 0.01) and waist circumference (mean change 
of −0.78 cm, p = 0.04) only in the improved group. These parameters remain unchanged in the non-improved 
group. As expected, the glycemic indices improved significantly only in the improved group [HbA1c, HOMA-IR 
(p < 0.01 for both) and QUICKI (p < 0.05)]. No significant changes in glycemic indices over time were seen 
Parameters
Non-improved Group Improved Group PA
Baseline Follow-Up Baseline Follow-Up
% Change in FG 1.57 (3.4) −22.00 (10.6) —
Age (years) 43.37 ± 8.8 43.32 ± 9.4 0.97
Weight (kg) 81.1 ± 13.0 82.51 ± 13.2 79.83 ± 14.8 78.4 ± 14.3** 0.55
BMI (kg/m2) 31.5 ± 5.2 32.1 ± 5.8 31.3 ± 5.5 30.7 ± 5.5* 0.79
Waist (cm) 102.2 ± 12.3 103.0 ± 13.2 99.2 ± 13.3 98.4 ± 13.7* 0.19
Hips (cm) 110.6 ± 11.4 110.3 ± 10.1 107.5 ± 10.8 107.1 ± 10.8 0.20
SBP (mmHg) 124.2 ± 12.5 125.8 ± 16.4 123.2 ± 16.0 120.3 ± 19.7 0.70
DBP (mmHg) 77.0 ± 9.0 78.3 ± 10.8 78.6 ± 11.0 77.0 ± 11.9 0.27
FG (mmol/l) 6.3 ± 0.5 6.3 ± 0.5 6.1 ± 0.4 5.0 ± 0.6** 0.02
Insulin (μU/ml) 16.1 (6.0,27.9) 13.9 (6.8,28.5) 18.0 (5.7,30.3) 14.4 (6.1,27.5) 0.70
HbA1c (%) 5.9 ± 0.8 6.2 ± 1.1 5.77 ± 0.5 4.98 ± 1.5** 0.35
HOMA-IR 4.2 (1.7,8.3) 3.8 (1.9,8.1) 4.95 (1.7,8.6) 3.13 (1.4,6.2)** 0.85
QUICKI 0.55 ± 0.1 0.56 ± 0.1 0.58 ± 0.2 0.65 ± 0.2* 0.49
McAuley ISI 5.72 (4.4,7.1) 6.12 (4.4,6.9) 5.40 (4.3,7.4) 5.96 (4.5,7.7) 0.65
TG (mmol/l) 1.6 (1.2,2.1) 1.6 (1.3,2.3) 1.63 (1.1,2.3) 1.51 (1.2,2.1) 0.80
Cholesterol (mmol/l) 4.9 ± 1.1 4.9 ± 1.1 4.82 ± 1.4 4.84 ± 1.2 0.83
HDL-C (mmol/l) 1.2 ± 0.4 1.0 ± 0.4* 1.06 ± 0.4 0.94 ± 0.3* 0.14
LDL-C (mmol/l) 2.7 (2.3,3.6) 2.9 (2.2,3.8) 2.8 (2.2,3.6) 3.13 (2.4,3.7) 0.78
SPX (pg/ml) 172 (138,198) 153 (131,190) 164 (136,227) 176 (146,285)** 0.97
Table 1. Baseline and Follow-Up Characteristics of Participants According to Groups. Note: % change in 
FG (follow-up – baseline) is represented as median (Inter-quartile range). Rest of the data is presented as 
Mean ± SD for continuous normal variables and medians (25th–75th percentile) for continuous non-normal 
variables. HOMA-IR, QUICKI and McAuley ISI are indices for insulin resitance and insulin sensitivity. Paired 
T-test and Wilcoxon signed-rank test was used to see differences across time points within groups; *denotes 
significance at p < 0.05; **denotes significant at p < 0.01 level, PA represents difference two groups at baseline 
(calculated by independent sample t-test and Mann-Whitney U-test for Gaussian and non-Gaussian variables, 
respectively).
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in the non-improved group except for HbA1c which increased significantly (p = 0.01). No significant changes 
were seen in the lipid indices over time in both groups except HDL-cholesterol, which decreased significantly in 
both groups. SPX levels [median (Q1, Q3)] increased significantly over time in the improved group [176 pg/ml 
(146,285) vs 164 pg/ml (136,227), p < 0.01]. No significant changes in SPX were observed in the non-improved 
group. Supplementary Fig. 1 shows the increase in SPX levels according to quartiles FG.
Clinical characteristics of the groups according to sex. Table 2 shows the sex-specific changes in 
the clinical characteristics of both groups over time. As expected, mean fasting glucose levels decreased signifi-
cantly in the improved group (mean change of −1.1 mmol/l, p < 0.01 and −1.39 mmol/l, p < 0.01 in females and 
males, respectively). HOMA-IR and QUICKI also improved in this group but in a sex-dimorphic manner, where 
HOMA-IR decreased and QUICKI increased significantly only in females. HbA1c levels in this group decreased 
significantly in both females (p < 0.01) as well in males (p < 0.05). All glycemic indices remain unchanged statis-
tically in both sexes in the non-improved group.
Both weight and BMI improved significantly only in males in the improved group (mean changes of −1.93 kg 
and −0.65 kg/m2, both p < 0.01, respectively) while waist circumference improved only in females in this group 
(mean change of −1.13 cm, p < 0.01). These significant changes were not seen in the non-improved group. 
HDL-cholesterol decreased significantly post-intervention in both female groups over time.
Levels of circulating SPX increased significantly only in the females of the improved group over time (p < 0.01) 
while in males, the increase in SPX levels was not significant. The SPX levels in both males and females in the 
non-improved group did not significantly change over time.
Figure 1 shows the circulating levels of fasting glucose (1 A) and SPX (1B) in the two groups at baseline and 
post-intervention, according to sex. Fasting glucose reduced significantly in both males and females over time in 
the improved group while SPX levels increased significantly in only females.
Intervention Effects in SPX and glycemic indices. Table 3 shows the intervention effects in the two 
groups stratified according to sex. As expected, fasting glucose improved significantly in both sexes in the 
improved group. Insulin resistance index (HOMA-IR) decreased significantly in only one of the four sub-groups 
(females in the improved group, mean change of −0.22, p < 0.01) and this significant decrease was also seen 
in females when all the subjects were taken into consideration (mean change of −0.12, p = 0.02). The insulin 
sensitivity index (QUICKI) also improved in females of the improved group, not in males. Lastly, SPX increased 
significantly over time only in females of the improved group.
Sex-specific associations of SPX with glycemic indices at both time points. Table 4 shows 
the results of regression analysis using SPX as dependent variable and glycemic indices as independent varia-
bles. Post-intervention data points were used to construct this analysis. Model D was constructed after adjust-
ments with BMI, age and fasting glucose. In all participants, circulating SPX levels showed a significant inverse 
Parameters
Non-Improved Group [N = 80] Improved Group [N = 80]
Females [N = 41] Males [N = 39] Females [N = 55] Males [N = 25]
Baseline 6 Months Baseline 6 Months Baseline 6 Months Baseline 6 Months
Weight (kg) 79.8 ± 11.6 81.5 ± 11.9 82.2 ± 14.1 83.4 ± 14.3 76.6 ± 15.2 75.4 ± 14.6 87.0 ± 11.0 85.1 ± 11.0**
BMI (kg/m2) 33.4 ± 5.2 34.1 ± 5.5 29.8 ± 4.7 30.3 ± 5.4 31.6 ± 5.8 31.1 ± 5.7 30.5 ± 4.6 29.9 ± 4.8**
Waist (cm) 98.4 ± 12.4 98.5 ± 13.5 106.8 ± 10.7 108.6 ± 10.8 95.3 ± 13.2 94.2 ± 13.4* 108.2 ± 8.7 108.3 ± 8.6
Hips (cm) 113.3 ± 8.7 112.4 ± 9.3 107.3 ± 13.4 107.9 ± 10.7 108.2 ± 11.8 108.0 ± 11.2 105.6 ± 7.4 104.4 ± 9.7
SBP (mmHg) 122.8 ± 13.7 123.7 ± 16.7 125.6 ± 11.0 128.1 ± 16.0 121.2 ± 15.1 118.4 ± 22 128.1 ± 17.2 124.8 ± 12.0
DBP (mmHg) 77.4 ± 10.6 76.3 ± 12 76.5 ± 7.0 80.3 ± 9.2 77.5 ± 11.7 76.9 ± 13.4 81.1 ± 9 77.2 ± 7.7
FG (mmol/l) 6.4 ± 0.5 6.4 ± 0.5 6.3 ± 0.5 6.3 ± 0.5 6.0 ± 0.4 4.9 ± 0.7** 6.4 ± 0.3 5.1 ± 0.2**
Insulin (μU/ml) 12.8 (6,26) 11.0 (6,17) 17.1 (12,33) 17.1 (12,31) 14.4 (5,26) 9.5 (3,17) 27.2 (15,39) 27.1 (20,43)
HbA1c (%) 5.88 ± 0.4 6.12 ± 1.1 5.87 ± 1.1 6.33 ± 1.1 5.6 ± 0.3 4.8 ± 1.2** 6.2 ± 0.6 5.4 ± 2.0*
HOMA-IR 3.5 (1.6,7.6) 3.2 (1.7,4.9) 4.6 (3,8.6) 4.8 (3.1,8.5) 3.7 (1.3,6.7) 2.2 (0.7,3.4)** 7.6 (3.8,11.5) 6.2 (4.5,9.3)
QUICKI 0.59 ± 0.2 0.58 ± 0.2 0.52 ± 0.1 0.53 ± 0.2 0.64 ± 0.2 0.75 ± 0.3* 0.48 ± 0.1 0.48 ± 0.1
McAuley ISI 6.46 (4.8,7.8) 6.33 (5.3,7.2) 4.80 (4.1,7.0) 4.69 (4.2,6.3) 6.04 (4.7,8.7) 6.75 (5.5,9.5) 4.45 (4.0,6.2) 4.61 (4.0,4.9)
TG (mmol/l) 1.5 (1.2,2) 1.4 (1.2,2) 1.7 (1.3,2.6) 1.9 (1.4,2.3) 1.4 (1.0,1.2) 1.4 (1.1,1.9) 2.2 (1.6,2.5) 2.0 (1.2,2.7)
Chol. (mmol/l) 5.2 ± 1.2 5.1 ± 1.2 4.6 ± 1 4.7 ± 1.0 4.8 ± 1.2 4.9 ± 1.2 4.9 ± 1.7 4.8 ± 1.3
HDLC (mmol/l) 1.2 ± 0.4 1.12 ± 0.4* 1.1 ± 0.4 1.0 ± 0.4 1.1 ± 0.4 1.0 ± 0.4* 0.9 ± 0.4 0.8 ± 0.2
LDLC (mmol/l) 2.9 (2.4,3.8) 3.09 (2.6,4.1) 2.6 (1.9,3) 2.65 (2.1,3.6) 2.79 (2.1,3.6) 3.12 (2.5,3.7) 2.99 (2.5,3.5) 3.25 (2.3,3.9)
SPX (Pg/ml) 172 (140,213) 157 (137,185) 168 (134,191) 142 (124,190) 159 (127,252) 182(152,369) ** 165 (144,205) 171 (145,199)
Table 2. Sex-Specific Changes in Clinical Characteristics of Groups Over Time. Note: Data presented as 
Mean ± SD for continuous normal variables and medians (25th percentile, 75th percentile) for continuous non-
normal variables. HOMA-IR, QUICKI and McAuley ISI are indices for insulin resitance and insulin sensitivity. 
Paired samples t-test and Wilcoxon signed-rank test is used to test the differences in central tendency for 
continous normal and non-normal variables respectively. FG and SPX referes to fasting blood glucose and 
Spexin respectively. P < 0.05 is taken as significant. *Depicts p-value < 0.05 and **depicts p-value < 0.01.
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association with fasting glucose levels even after adjustments for age and BMI (standardized β = −0.17, p = 0.001). 
Stratified according to sex, this significant association was observed only in females (β = −0.22, p = 0.003) and 
not in males (β = −0.09, p = 0.28). The same trend was observed with insulin and HOMA-IR, where the inverse 
association was significant even after adjustments for age, BMI and fasting glucose (Model D). The inverse associ-
ation of SPX with HbA1c lost statistical significance after adjustment with fasting glucose values. QUICKI showed 
a significant positive association with SPX even after adjustments in females only (β = 0.35, p < 0.01).
Figure 2 shows the associations between SPX and the glycemic indices: fasting glucose (2A), insulin (2B) and 
HOMA-IR (2 C) on X-axis. Significant inverse correlations between SPX and glycemic indices were seen only in 
females.
Discussion
The present study investigated the circulating levels of SPX before and after a 6-month lifestyle modification 
program on adults with prediabetes and suggests that SPX increased significantly over time but only in women 
with a significant improvement in their fasting glucose. To our knowledge, the present study is the first to evaluate 
changes in circulating levels of SPX after a 6-month lifestyle intensive program on people with prediabetes and 
certainly the first in an Arab ethnic population where the prevalence of prediabetes is high14.
The significant decrease in fasting glucose levels in the improved group was associated with a significant 
increase in circulating levels of SPX. This is in accordance with previous findings that serum SPX levels are low in 
T2DM and correlate inversely with glucose levels15,16. As SPX is a relatively new biomarker, its role in humans and 
knowledge on the regulation of its expression is still emerging. Recent reports suggest its presence in pancreatic 
β cells and found negative feedback between the administration of glucose and release of SPX from pancreatic 
islets17. The mechanism driving this negative feedback is unclear as there is not much information on SPX recep-
tors. However, these previous results and ours support the theory that SPX plays a role in glucose homeostasis and 
may serve as a biomarker for impaired glucose regulation seen in diabetes. The authors acknowledge that there 
are studies which do not support the role of SPX in glucose homeostasis18. This discrepancy between the results of 
our study and the previous one may be due to differences in study population and metabolic profile (adults with 
prediabetes versus normoglycemic adolescents18).
The significant inverse association of SPX with glucose remained even after adjustments for BMI and age. A 
significant inverse association of SPX was also seen with other glycemic indices like insulin and HOMA-IR, only 
in women, independent of fasting glucose. The significant decrease in HOMA-IR with an increase in SPX levels 
in this study confirms our previous work where SPX was found to be significantly lower in metabolic syndrome 
(MetS) group compared to the non-MetS group, particularly in women19, knowing that IR is a central component 
of MetS20. Our previous study on pregnant women also confirms this association only among subjects without 
gestational diabetes mellitus (GDM) indicating a reversal of SPX role in the presence of considerable damage to 
insulin-regulating mechanisms of the pancreas21. In both studies, the protective role of SPX as an insulin sensi-
tizer appears only true among subjects without established diabetes. Some other studies conducted on rodents 
confirmed that SPX administration effectively attenuates IR8. The mechanism behind this attenuation of IR by 
SPX is not yet fully understood. However, recent studies discovered that SPX and Galanin (GAL) are in the same 
Figure 1. Changes in levels of fasting glucose and spexin overtime. Data presented as Mean ± SD for fasting 
glucose (A) and median (25th percentile, 75th percentile) for SPX (B). NG and IG represent non-improved 
and improved groups respectively while F and M represents females and males respectively. **Depicts 
p-value < 0.01.
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Study Groups Intervention Effects: Mean Change, p
Gr 1 (N = 80) Gr 2 (N = 80)
F (6M vs B) M (6M vs B) Gr 1 (6M vs B) Gr 2 (6M vs B)F (N = 41) M (N = 39) F (N = 55) M (N = 25)
Fasting Glucose
Baseline 6.37 (0.07) 6.26 (0.06) 6.00 (0.06) 6.44 (0.09)
−0.54, <0.01 −0.69, <0.01 0.02, 0.69 −1.25, <0.016-months 6.39 (0.08) 6.27 (0.07) 4.90 (0.07) 5.06 (0.10)
6M vs B 0.03, 0.74 0.02, 0.83 −1.1, <0.01 −1.4, <0.01
Log insulin
Baseline 1.06 (0.08) 1.23 (0.08) 1.01 (0.07) 1.34 (0.09)
−0.08, 0.13 0.06, 0.34 −0.02, 0.78 −0.01, 0.946-months 1.03 (0.08) 1.24 (0.08) 0.89 (0.07) 1.46 (0.09)
6M vs B −0.03, 0.66 0.01, 0.97 −1.12, 0.08 0.11, 0.22
Log HOMA-IR
Baseline 0.51 (0.08) 0.67 (0.08) 0.43 (0.07) 0.80 (0.09)
−0.12, 0.02 0.00, 0.95 −0.02, 0.79 −0.11, 0.066-months 0.48 (0.07) 0.67 (0.08) 0.21 (0.07) 0.81 (0.09)
6M vs B −0.03, 0.68 0.00, 0.98 −0.22, <0.01 0.01, 0.96
QUICKI
Baseline 0.59 (0.03) 0.52 (0.04) 0.64 (0.03) 0.48 (0.04)
0.06, 0.04 0.01, 0.85 0.01, 0.76 0.05, 0.076-months 0.58 (0.04) 0.53 (0.04) 0.75 (0.04) 0.47 (0.05)
6M vs B −0.01, 0.97 0.01, 0.65 0.12, <0.01 −0.01, 0.88
Log SPX
Baseline 2.25 (0.03) 2.25 (0.03) 2.28 (0.03) 2.24 (0.04)
0.06, 0.04 −0.002, 0.97 0.004, 0.90 0.05, 0.186-months 2.28 (0.05) 2.24 (0.05) 2.37 (0.04) 2.26 (0.06)
6M vs B 0.03, 0.62 −0.02, 0.73 0.09, 0.04 0.01, 0.84
Table 3. Intervention Effects in SPX and Glycemic Indices. Note: Data presented as Mean (Standard error) 
for baseline and 6-months. 6 M, B, F, M, Gr1,Gr2, HOMA-IR and QUICKI represents 6-months, baseline, 
female, male, non-improved group, improved group, insulin resitance and insulin sensitivity index respectively. 
Changes at time-intervals are presented as mean change and associated p-value. Two-way repeated measures 
ANOVA was used for testing intervention effects. P < 0.05 is taken as significant.
Model
All Subjects [N = 160] Females [N = 96] Males [N = 64]
β 95% CI p β 95% CI p β 95% CI p
GLUCOSE
A −0.18 −0.09, −0.02 0.001 −0.20 −0.11, −0.02 <0.001 −0.09 −0.09,0.03 0.30
B −0.18 −0.10, −0.03 0.001 −0.22 −0.12, −0.03 0.002 −0.09 −0.09,0.03 0.30
C −0.17 −0.10, −0.02 0.001 −0.22 −0.12, −0.03 0.003 −0.09 −0.09,0.03 0.28
INSULIN
A −0.16 −0.15, −0.02 0.01 −0.22 −0.21, −0.03 0.008 −0.06 −0.16,0.08 0.53
B −0.16 −0.16, −0.02 0.01 −0.25 −0.23, −0.05 0.003 −0.05 −0.15,0.09 0.59
C −0.15 −0.15, −0.01 0.02 −0.25 −0.23, −0.05 0.003 −0.04 −0.14,0.09 0.72
D −0.15 −0.15, −0.01 0.02 −0.28 −0.23, −0.05 0.003 −0.03 −0.14,0.10 0.78
HOMA-IR
A −0.16 −0.15, −0.02 0.01 −0.23 −0.21, −0.04 0.005 −0.06 −0.16,0.08 0.54
B −0.17 −0.16, −0.02 0.009 −0.27 −0.23, −0.06 0.002 −0.05 −0.16,0.09 0.61
C −0.16 −0.15, −0.02 0.01 −0.27 −0.24, −0.06 0.002 −0.03 −0.14,0.10 0.76
D −0.15 −0.15, −0.01 0.02 −0.25 −0.23, −0.05 0.003 −0.03 −0.14,0.10 0.78
QUICKI
A 0.24 0.08,0.47 <0.01 0.32 0.09,0.57 <0.01 0.02 −0.4,0.50 0.90
B 0.25 0.08,0.48 <0.01 0.35 0.13,0.60 <0.01 0.01 −0.5,0.49 0.95
C 0.23 0.06,0.48 0.01 0.36 0.13,0.61 <0.01 0.01 −0.4,0.47 0.96
D 0.23 0.06,0.46 0.01 0.35 0.11,0.61 <0.01 −0.03 −0.5,0.41 0.83
Table 4. Regression Analysis using log SPX as Dependent Variable and Glycemic Indices as Independent 
Variables. Note: Data presented as standardized β, 95% CI and associated p-values. HOMA-IR and QUICKI 
are indices for insulin resitance and insulin sensitivity respectively. Model A is univariate, Model B adjusted for 
BMI, Model C adjusted for +age, and Model D adjusted for fasting glucose. Significant at p < 0.05.
6Scientific RepoRts |          (2019) 9:9454  | https://doi.org/10.1038/s41598-019-46006-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
family of peptides and SPX binds to and activates GAL receptor 2 (GALR2) and GAL receptor 3 (GALR3)22, and 
the finding that GAL antagonist M35 significantly increased IR due to its inhibition of movement of glucose 
transporter 4 (GLUT4)23,24 provides indirect evidence for involvement of SPX in improving insulin sensitivity.
In the present study, fasting glucose levels reduced significantly in both males and females of the improved 
group post intervention, yet SPX levels significantly increased only in females. The sexual dimorphism observed 
in SPX levels post intervention may be due to the known gender differences in insulin sensitivity and glucose 
metabolism owing to the regulatory effects by different sex steroids25. Striking sexual differences in glucose 
metabolism have been reported in studies which conclude that obese men have higher hepatic IR than obese 
women26 which explains, in part, the higher prevalence of diabetes in men. Besides, recent studies advocate a 
role of SPX in fat tissue metabolism and lipid homeostasis27. Although lipid indices showed no correlation with 
circulating levels of SPX in the present study, the fact that there are sex-specific differences in lipid metabo-
lism28 explains indirectly the sexual disparity observed and must be further evaluated in future studies. Several 
other mechanisms including the estrogen effect on IR29 and differences in glucoregulatory hormones such as 
growth hormone30 may explain this disparity. The sex-specific improvements in IR with an increase in SPX levels 
observed in this study may have clinical relevance and should be further explored.
Among the participants recruited in this study, 18.1% (n = 29) were on metformin for 6-months, aside 
from the lifestyle modification intervention. Metformin is known to alleviate IR mainly by improving 
insulin-mediated suppression of hepatic glucose production31. Re-analysis of data without participants on met-
formin (Supplementary Table 1) showed that the sex-specific increase and decrease in circulating levels of SPX 
and HOMA-IR, respectively, is independent of metformin supplementation.
This 6-month lifestyle intervention program focused mainly on the reduction of fasting glucose, weight loss 
and increase in physical activity. It resulted in a significant increase in SPX levels and a subsequent significant 
decrease in body weight and BMI in the improved group. These results are in line with the reports that suggest 
SPX is involved in weight regulation6,9. In fact, synthetic SPX treatment in dietary-induced obese (DIO) mice 
models has been consistently shown to reduce body weight possibly by its inhibition of fatty acid uptake into 
hepatocytes8,32. This has not been tried in humans yet. However, such studies, in addition to the findings observed 
in our data, suggest a possibility of a potential application of SPX treatment for reducing the glucose load (e.g. in 
impaired glucose regulation and diabetes) and obesity treatment (e.g. weight control, treatment of fatty liver, etc.) 
and may be useful in treating diseases such as metabolic syndrome. However, the results from many more animal 
and in-vitro studies are warranted to establish the role of this hormone in glucose and body-weight homeostasis.
Strengths of this study include its prospective design; measurement of SPX at different time intervals in the 
same laboratory; and the ethnic homogeneity of the study participants. The authors do acknowledge some limi-
tations. The relatively higher number of female participants (n = 96) than males (n = 64) and the other one being 
its relatively short intervention period. The authors acknowledge the possibility that a non-significant increase 
in SPX levels in males in the improved group may be due to the small sample size. Furthermore, whether the 
observed elevations in SPX levels are true for DM patients with improved glycemic control cannot be ascertained. 
The stringent criteria for inclusion in this study limit its applicability only on people with prediabetes. Lastly, 
objective information on changes in dietary habits, physical activity, and body fat/muscle distribution of the study 
participants were not available in this study and should be evaluated in further studies. Nevertheless, this is the 
first study to demonstrate changes in circulating levels of SPX in people who responded favorably to a 6-month 
lifestyle intervention program, particularly in females.
Conclusion
In conclusion, increased circulating SPX levels among adults with prediabetes are observed following favorable 
glycemic changes post-lifestyle modification program, particularly in females. Further investigations are needed 
using larger sample sizes to shed light whether unknown mechanisms are at play supporting the sex-dimorphic 
changes. The study also suggested that SPX levels correlate inversely with fasting glucose and HOMA-IR 
Figure 2. Association of spexin with glycemic indices. Fasting glucose (A), insulin (B) and HOMA-IR (C) 
on X-axis and spexin on Y-axis. Significant inverse correlations between SPX and glycemic indices were seen 
only in females. “r” depicts pearson correlation coefficient and “p” is the associated p-value. P-value < 0.05 is 
considered significant.
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independent of age and BMI among adults with prediabetes. Our data suggests a possible role of SPX as a marker 
of glycemia and has potential use as anti-glycemic drug.
Methods
subjects. A total of 160 subjects were randomly selected from an already existing cohort (prediabetes study) 
of 294 adult Saudi male and female subjects (age range 25–60) with impaired glucose regulation attending a 
lifestyle intervention program published previously33. This lifestyle intervention program was conducted by the 
Chair for Biomarkers of Chronic Diseases (CBCD), King Saud University (KSU) at two tertiary hospitals located 
in Riyadh, Saudi Arabia. The program was conducted from April 2013 till March 2017. The inclusion criteria for 
this program was a fasting glucose level of 5.6–6.9 mmol/l (impaired glucose regulation or prediabetes). Pregnant 
women and subjects with known DM; renal, hepatic, pulmonary or neurologic complications were excluded.
Intervention. The lifestyle modification program (prediabetes study) has been previously published33. Briefly, 
eligible subjects with impaired glucose regulation had an orientation session conducted by a physician and die-
tician and were educated about the risk of developing T2DM. Information on their usual dietary habits and 
physical activity were noted and were advised some modifications in their lifestyle like increased physical activ-
ity, weight reduction of at least 5% or more, reduction of total fat intake to <30% of the energy consumed and 
increased fiber intake. Dietary charts, booklets, etc., prepared and translated from successful lifestyle interven-
tion programs done elsewhere34,35 were distributed in order to achieve the objectives. Pedometers (081564483, 
Patterson Medical) were distributed to participants and advised to take at least 5000 steps per day. The interven-
tion was monitored regularly via phone calls to the participants; however, a “self-monitoring” approach36,37 was 
largely followed.
Anthropometry and clinical assessment. Information on anthropometrics (at baseline and 6-months) 
was extracted from the pre-diabetes database. Briefly, at baseline and after 6-months of intervention, subjects 
were advised to visit their recruiting center after an overnight fast for anthropometry and blood withdrawal by 
trained nurses. Anthropometry included waist and hip circumference (cm) using a standardized measuring tape. 
Weight (kg) and height (cm) were measured using a standardized digital scale and BMI was calculated as weight 
(kg)/height (m2). Blood pressure (mmHg) was measured twice using standard methods and the average read-
ing was recorded. Fasting blood samples, taken at each time point, were processed immediately using standard 
procedures and transported to CBCD, KSU where they were aliquoted and stored at −80 °C for further analysis.
Biochemical Measurements. Biochemical measurements for baseline and 6-months were also retrieved 
from the database. Fasting glucose, lipid profile, calcium and phosphorus in the samples for both time points 
were measured using a routine biochemistry analyzer, Konelab 20 (Thermo-Fischer Scientific, Helsinki, Finland) 
(catalogue# 981379 for glucose; #981812 for total cholesterol; #981823 for HDL-cholesterol; #981301 for tri-
glycerides; #981772 for calcium and #981890 for phosphorus). The imprecision, calculated as the total CV, was 
between 3–5% in all tests. LDL-cholesterol was calculated using the Friedwald equation38. DCA vantage ana-
lyzer (Siemens, Munich, Germany) with the imprecision of <3.5% was used to measure glycated haemoglobin 
(HbA1c). Fasting insulin was quantified by Luminex Multiplex (Luminexcorp, Texas, USA) using fluorescent 
microbead technology.
For this study specifically, spexin was quantified using commercially available assay kits, supplied by Phoenix 
Pharmaceuticals (Burlingame, California) (catalog# EK-023-81). The imprecision for this procedure is <10% and 
has a 0% cross-reactivity with related human peptides like preprospexin, ghrelin, etc.
Figure 3. Study Flowchart.
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Study groups. For the current study, 160 participants, mentioned earlier were subdivided into two groups 
(1:1) based on the improvement in levels of circulating fasting glucose from baseline to end of study. 80 subjects 
with the highest improvement in terms of reduction in fasting glucose was placed in one of the groups (improved 
group) and the rest of the subjects (80) was placed in the non-improved group. This division into groups was 
done to investigate the hypothesized change in circulating levels of SPX vis-à-vis improvement in fasting glucose. 
Changes in other glycemic indices like insulin, HbA1c and Homeostatic model assessment for insulin resistance 
(HOMA-IR) {calculated as [fasting insulin (mU/l) × fasting glucose (mmol/l)/22.5)39 was also seen. Besides two 
other indices of insulin sensitivity namely Quantitative insulin sensitivity check index (QUICKI)40 and McAuley 
insulin sensitivity index (McAuley ISI)41 was calculated as below:
= +
= . − . − .⁎ ⁎
QUICKI 1/{ log(fasting insulin) log(fasting glucose)}
McAuley ISI exp{2 63 0 28 ln(fasting insulin) 0 31 ln(fasting triglycerides)}
A flowchart depicting the course of this study is provided in Fig. 3.
Data analysis. G*Power calculator was used to determine sample size. Based on the repeated measure-
ment analysis, the actual observed power was >0.90 for a sample size of 150. Data was analyzed using SPSS 21 
(Chicago, IL, USA). Each variable was tested for normality using Shapiro-Wilk test. Continuous Gaussian vari-
ables were shown as mean ± standard deviation (SD) while continuous non-Gaussian variables were expressed 
as median (quartiles 1 and 3). Baseline differences between groups were calculated using independent Student 
T-test and Mann-Whitney U-test for normal and non-normal variables, respectively. Paired samples T-test and 
Wilcoxon signed-rank test were used to test differences between baseline and after 6 months, for normal and 
non-normal continuous variables, respectively. Non-normal variables were log-transformed before parametric 
analysis. Pearson correlation was used to determine associations between SPX and other variables at both time 
points. Two-way repeated measured ANOVA was performed to test the differences between the groups and sexes 
overtime. Regression analysis was done using log SPX as dependent variable and glycemic indices (fasting glu-
cose, insulin, HbA1c, and HOMA-IR) as independent variables. Significance was set at p < 0.05. Microsoft Excel 
2010 was used to plot the figures.
Details of ethics approval. All the procedures followed in this study were in accordance with the ethical 
standards of the responsible committee on human experimentation (institutional and national) and with the 
Helsinki Declaration of 1975, as revised in 2008. The study was approved by the Ethics Committee of College of 
Science, King Saud University.
Statement of informed consent. Written informed consent was obtained from each participant in this 6 
month interventional study.
Data Availability
The dataset analysed for getting the results observed in this study is available from the corresponding author on 
reasonable request.
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